Extracellular vesicle secretome from mesenchymal stromal cells prevents post-ischemic heart failure by targeting cardiac fibrosis.
Summary
The investigators developed a good manufacturing practice-compatible extracellular-vesicle-enriched secretome from mesenchymal stromal cells using a laminin-521-based production strategy. The product reduced myofibroblast activation and fibrosis, preserved left ventricular ejection fraction, and promoted reparative macrophage polarization in murine ischemia-reperfusion models, with cardioprotection also observed after intracoronary administration in pigs. A PDGFRβ-targeted PET platform was linked to the therapeutic framework for longitudinal assessment of fibrotic activity.
Key Findings
- A laminin-521-based process generated a GMP-compatible extracellular-vesicle-enriched secretome from mesenchymal stromal cells.
- Treatment preserved left ventricular ejection fraction and reduced PDGFRβ-associated myofibroblast activation and cardiac fibrosis in murine ischemia-reperfusion injury.
- Intracoronary administration was cardioprotective in a clinically relevant porcine model, while PDGFRβ-targeted PET enabled longitudinal assessment of fibrotic activity.
Clinical Implications
The findings support further development of cell-free extracellular-vesicle therapies and PET-guided personalization after myocardial infarction. Translation will require formal toxicology, pharmacokinetic, biodistribution, dose-finding, and randomized clinical studies before clinical use.
Why It Matters
The study integrates scalable manufacturing, mechanistic therapy, large-animal validation, and molecular imaging into a coherent translational platform for post-infarction heart failure. It directly targets fibrosis, an important pathway that remains inadequately addressed after reperfusion.
Limitations
- The provided abstract does not report the exact numbers of animals or human participants.
- Human PET observations were preliminary and did not test therapeutic efficacy in patients.
- Long-term safety, biodistribution, immunogenicity, and dose-response relationships remain to be established.
Future Directions
Future research should complete regulatory preclinical testing, define optimal dosing and administration timing, evaluate biodistribution and arrhythmogenic or immunologic risks, and conduct early-phase clinical trials using PET-defined fibrotic phenotypes for patient selection.
Study Information
- Study Type
- Cohort
- Research Domain
- Treatment
- Evidence Level
- III - Preclinical translational therapeutic study supported by complementary in vitro, murine, porcine, and preliminary human imaging data.
- Study Design
- OTHER